deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03332498

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions Colon Cancer Colon Disease Colorectal Cancer Colorectal Carcinoma
Interventions Ibrutinib Pembrolizumab
Updated 21 times since 2017 Last updated: Jun 1, 2022 Started: Jan 24, 2018 Primary completion: Dec 5, 2019 Completion: Sep 9, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03332498, this PHASE1/PHASE2 trial focuses on Colon Cancer and Colon Disease and remains completed. Sponsored by H. Lee Moffitt Cancer Center and Research Institute, it has been updated 21 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2022 — Jul 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Apr 2022 — Jun 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 16 earlier versions

  1. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Mar 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Nov 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  15. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Dec 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • H. Lee Moffitt Cancer Center and Research Institute
  • Janssen Scientific Affairs, LLC
  • Merck Sharp & Dohme LLC
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations